Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying users area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Moderna Inc., consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income (loss)
Stock-based compensation
Depreciation and amortization
Leased assets expensed
Amortization/accretion of investments
Deferred income taxes
Other non-cash items
Accounts receivable
Prepaid expenses and other assets
Inventory
Right-of-use assets, operating leases
Accounts payable
Accrued liabilities
Deferred revenue
Income taxes payable
Deferred lease obligation
Operating lease liabilities
Other liabilities
Changes in assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities
Purchases of marketable securities
Proceeds from maturities of marketable securities
Proceeds from sales of marketable securities
Purchases of property, plant and equipment
Investment in convertible notes and equity securities
Decrease in restricted cash
Net cash used in investing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
Proceeds from offerings of common stock, net of issuance costs
Repurchases of redeemable convertible preferred stock
Proceeds from issuance of common stock through equity plans
Repurchases of common stock
Charges to financing lease liabilities
Reimbursement of assets under financing lease obligation
Payments on financing lease obligation
Net cash provided by (used in) financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of year
Cash, cash equivalents and restricted cash, end of year

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Moderna Inc. net cash provided by (used in) operating activities increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Moderna Inc. net cash used in investing activities decreased from 2020 to 2021 but then slightly increased from 2021 to 2022.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Moderna Inc. net cash provided by (used in) financing activities decreased from 2020 to 2021 and from 2021 to 2022.